PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 58 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $65,000 | -33.7% | 107,953 | +188.2% | 0.00% | – |
| Q4 2021 | $98,000 | +127.9% | 37,452 | +169.3% | 0.00% | – |
| Q3 2021 | $43,000 | -71.3% | 13,907 | -65.6% | 0.00% | – |
| Q2 2021 | $150,000 | +76.5% | 40,384 | +63.3% | 0.00% | – |
| Q1 2021 | $85,000 | -34.1% | 24,724 | -35.6% | 0.00% | – |
| Q4 2020 | $129,000 | +14.2% | 38,393 | +18.4% | 0.00% | – |
| Q3 2020 | $113,000 | -13.1% | 32,427 | +15.1% | 0.00% | – |
| Q2 2020 | $130,000 | – | 28,164 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |